Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

Phase 2

Completed

• Conditions: Gastroenteritis
• Interventions: Biological: HIL-214

• Registration Number: NCT05972733
• Lead Sponsor: HilleVax

Brief Summary

The purpose of this trial is to obtain serum for proficiency testing to confirm assay validity is maintained following the dosing of adults with a pediatric dose of HIL-214.

Detailed Description

This single-arm trial serves to obtain serum for proficiency testing to confirm assay validity is maintained. Exploratory aspects of this trial include evaluating additional assays used for the assessment of immune responses to HIL-214 in peripheral-blood samples. Given the large volume of blood required, the pediatric dose will be tested in healthy adults. The main scientific rationale for the trial is to identify immune assays that can assess the generation of serum antibodies or cell-mediated immunity (CMI) specific to norovirus strains not represented in the HIL-214 vaccine (i.e. cross-reactivity).

Study Timeline

• Study First Submitted: 2023-07-11
• Study First Submitted QC: 2023-07-31
• Study Start: 2023-08-02
• Study First Posted: 2023-08-02
• Primary Completion: 2023-08-14
• Study Completion: 2023-11-10
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-05
• Last Update Posted: 2024-01-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Male or female subjects aged 18 to 49 years, inclusive.
• Individuals who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
• The individual signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to regulatory requirements.
• Individuals willing and able to comply with trial procedures and are available for the duration of follow-up.

Read More

Exclusion Criteria

• Females who are pregnant or breastfeeding.
• Gastroenteritis within 14 days before planned dosing (can warrant delay of trial vaccine administration).
• Known hypersensitivity or allergy to any of the HIL-214 components (including excipients).
• Known or suspected impairment/alteration of immune function, including history of any autoimmune disease or neuro-inflammatory disease.
• Any serious chronic or progressive disease (including hepatitis B or C).
• Previous exposure to an experimental norovirus vaccine.
• Subject or subject's first-degree relatives are involved in the trial conduct.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open Arm Study	HIL-214	One dose given to all participants

Primary Outcome Measures

Name	Time	Method
Primary Immunogenicity for Panel Formation	6 months	For the 80 subjects enrolled in the trial, the serum samples that will be collected will be used to produce a proficient assay panel based on immunogenicity results of the initial testing. This panel that is formed will be used for further analysis in other clinical trials.

Trial Locations

Locations (2)

Clinical Research Atlanta; 🇺🇸 Stockbridge, Georgia, United States

Pennisula Research Associates; 🇺🇸 Rolling Hills Estates, California, United States